Last Updated:
Natco Pharma Q3 Results: Its consolidated revenue from operations in October-December 2024 stands at Rs 474.8 crore as compared to Rs 758.6 crore in the same period a year ago.
Natco Pharma Q3 Results: Formulation exports in the third quarter were lower at Rs 285.8 crore as compared to Rs 605.6 crore in the same period of the last fiscal year.
Natco Pharma Q3 Results: Natco Pharma Ltd has reported a 37.75 per cent decline in its consolidated net profit to Rs 132.4 crore in the December 2024 quarter, hit by a drop in formulations exports. Natco Pharma’s consolidated revenue from operations in October-December 2024 stood at Rs 474.8 crore as compared to Rs 758.6 crore in the same period a year ago.
Its net profit had stood at Rs 212.7 crore in the corresponding quarter last year, NATCO Pharma said in a regulatory filing.
Formulation exports in the third quarter were lower at Rs 285.8 crore as compared to Rs 605.6 crore in the same period of the last fiscal year. Formulation sales in the domestic market stood at Rs 96.1 crore, down from Rs 99.4 crore in the year-ago period, NATCO Pharma said in an investor presentation.
Shares of NATCO Pharma Ltd on Thursday slumped 20 per cent after the firm reported a 37.75 per cent decline in consolidated net profit in the December quarter.
Total expenses in the third quarter were lower at Rs 487.4 crore as compared to Rs 539.3 crore in the year-ago period, the company said.
On the other hand, API (active pharmaceutical ingredient) revenue stood at Rs 66.6 crore, up from Rs 46.3 crore in the corresponding quarter last fiscal year, it added.
The board of directors at their meeting held on Wednesday declared a third interim dividend of Rs 1.50 each per equity share of Rs 2 each for the financial year 2024-25, the company said.
